Sugi Predict

Sugi Predict / Compounds / SCHEMBL5535694

SCHEMBL5535694

SCHEMBL5535694

Cc1ccn(-c2cccc(Br)c2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ ATM Q13315 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ ALDH1A1 P00352 5/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ HTT P42858 3/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ MGLL Q99685 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ CNR1 P21554 2/20 0.40
▸ CNR2 P34972 2/20 0.40
▸ GPR55 Q9Y2T6 2/20 0.40
▸ POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30474527 1.00 MAPT (0.50) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL14412226 0.87 RAB9A (0.59) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL17640922 0.83 RAB9A (0.48) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL5101204 0.81 MEN1 (0.56) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL5535687 0.79 MGLL (0.41) MAPTSMN1; SMN2ATMALDH1A1MEN1
SCHEMBL122970 0.79 KEAP1 (0.53) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL30923114 0.79 MAPT (0.50) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL15352749 0.79 SMN1; SMN2 (0.41) MAPTSMN1; SMN2ATMALDH1A1MEN1
SCHEMBL2615990 0.79 NOTUM (0.53) MAPTRAB9ASMN1; SMN2NPC1ATM
SCHEMBL7333158 0.79 MAPT (0.50) MAPTRAB9ASMN1; SMN2NPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 — — US disclosed
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 — — US disclosed
CN-113354635-B Pyrrolidine integrin regulator and application thereof 清药同创(北京)药物研发中心有限公司 2023-04-18 — — CN disclosed
WO-2022086993-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC (US) 2022-04-28 — — WO disclosed
CN-113354635-A Pyrrolidine integrin regulator and application thereof 清药同创(北京)药物研发中心有限公司 2021-09-07 — — CN disclosed
WO-2020112937-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2020-06-04 — — WO disclosed
US-10450312-B2 Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-10-22 — — US disclosed
US-20180291022-A1 NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-10-11 — — US disclosed
US-10023568-B2 Naphthyridine derivatives useful as αvβ6 integrin antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-07-17 — — US disclosed
EP-2989100-B1 NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS GLAXOSMITHKLINE IP DEV LTD (GB) 2018-02-28 — — EP disclosed
CN-104583214-B The inhibitor of human immunodeficiency virus replication 百时美施贵宝公司 2017-06-09 — — CN disclosed
US-20160280705-A1 NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-09-29 — — US disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 — — EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834449-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 MAPT 1236/4885RAB9A 3462/4885SMN1; SMN2 1145/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885RAB9A 2824/4885SMN1; SMN2 3985/4885
US-20160280705-A1 NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS ITGB6, ITGA6, ITGB1 MAPT 4413/4885RAB9A 484/4885SMN1; SMN2 3233/4885
US-10450312-B2 Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists ITGB6, ITGA6, ITGB1 MAPT 4413/4885RAB9A 484/4885SMN1; SMN2 3233/4885
US-20180291022-A1 NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS ITGB6, ITGA6, ITGB1 MAPT 4413/4885RAB9A 484/4885SMN1; SMN2 3233/4885
US-10023568-B2 Naphthyridine derivatives useful as αvβ6 integrin antagonists ITGB6, ITGA6, ITGB3 MAPT 4049/4885RAB9A 682/4885SMN1; SMN2 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.